Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 40.97 and traded as low as GBX 38. Faron Pharmaceuticals Oy shares last traded at GBX 39, with a volume of 72,579 shares changing hands.
Faron Pharmaceuticals Oy Price Performance
The stock has a market capitalization of £77.09 million, a P/E ratio of -1.72 and a beta of 1.12. The business has a fifty day simple moving average of GBX 40.78 and a 200-day simple moving average of GBX 44.01. The company has a debt-to-equity ratio of 155.01, a quick ratio of 1.09 and a current ratio of 2.40.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
